Angiotensin-converting enzyme 2: virus accomplice or host defender?

被引:0
|
作者
Wang Jiyan [1 ]
Chang Hongkai [1 ]
Qiao Yaya [1 ]
Sun Huanran [1 ]
Li Xichuan [6 ]
Yuan Shuofeng [10 ]
Zhang Shuai [17 ]
Shan Changliang [1 ]
机构
[1] State Key Laboratory of Emerging Infectious Diseases
[2] Carol Yu Centre for Infection  12. Department of Microbiology  13. Li Ka Shing Faculty of Medicine 
[3] School of Integrative Medicine
[4] Tianjin University of Traditional Chinese Medicine  19. Tianjin 301617
[5] State Key Laboratory of Medicinal Chemical Biology
[6] College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research  3. Nankai University  4. Tianjin 300350 
[7] Tianjin Key Laboratory of Animal and Plant Resistance
[8] College of Life Sciences  8. Tianjin Normal University  9. Tianjin 300387
关键词
ACE2; asymptomatic infection; COVID-19; metabolism; SARS-CoV-2;
D O I
暂无
中图分类号
R511 [病毒传染病];
学科分类号
100401 ;
摘要
Objective: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to social disruptions, mainly because we know too little about SARS-CoV-2.Methods and Results: In this study, we integrated RNA sequencing results and found that SARS-CoV-2 infection alters aerobic glycolysis, the oxidative pentose phosphate pathway (oxiPPP), and DNA replication in lung tissues and cells. However, the direction of metabolic flux and DNA replication are dominated by angiotensin-converting enzyme 2 (ACE2), a host cell-expressed viral receptor protein. More interestingly, although hosts with a high expression of ACE2 are more likely to be infected with SARS-CoV-2, the invading virus cannot perform nucleic acid replication well due to the restriction of glucose metabolism, eventually resulting in a prolonged infection cycle or infection failure.Conclusion: Our findings preliminarily explain the reasons for the emergence of asymptomatic infections at an early stage, which will provide assistance for the development of detection methods for diagnosing COVID-19.
引用
收藏
相关论文
共 50 条
  • [31] Angiotensin-converting enzyme inhibitors
    Brown, NJ
    Vaughan, DE
    CIRCULATION, 1998, 97 (14) : 1411 - 1420
  • [32] ANGIOTENSIN-CONVERTING ENZYME IN SARCOIDOSIS
    GLATT, A
    MAYO CLINIC PROCEEDINGS, 1983, 58 (02) : 140 - 140
  • [33] INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME
    CUSHMAN, DW
    ONDETTI, MA
    CHEMTECH, 1982, 12 (10) : 620 - 624
  • [34] ANGIOTENSIN-CONVERTING ENZYME IN NEUROSARCOIDOSIS
    RUBINSTEIN, I
    HOFFSTEIN, V
    ARCHIVES OF NEUROLOGY, 1987, 44 (03) : 249 - 250
  • [35] SERUM ANGIOTENSIN-CONVERTING ENZYME
    BRUYNZEEL, PLB
    KRAMPS, JA
    TGO-TIJDSCHRIFT VOOR GENEESMIDDELENONDERZOEK-JOURNAL OF DRUG RESEARCH-JDR, 1983, 8 (08): : 2020 - 2024
  • [36] Signaling by the angiotensin-converting enzyme
    Fleming, I
    CIRCULATION RESEARCH, 2006, 98 (07) : 887 - 896
  • [37] Angiotensin-converting enzyme inhibitors
    Menard, J
    Patchett, AA
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56: DRUG DISCOVERY AND DESIGN, 2001, 56 : 13 - 75
  • [38] ACUTE AND CHRONIC EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS ON TISSUE ANGIOTENSIN-CONVERTING ENZYME
    CHAI, SY
    PERICH, R
    JACKSON, B
    MENDELSOHN, FAO
    JOHNSTON, CI
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1992, : 7 - 12
  • [39] Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Are Involved in Sinoaortic Denervation-Induced Cardiovascular Hypertrophy in Rats
    Zhang, Li-Chao
    Li, Zhen-Zhen
    Yu, Yong-Sheng
    Wang, Zhi-Bin
    Wei, Xin
    Su, Ding-Feng
    Li, Ling
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (09) : 1398 - 1403
  • [40] The polymorphisms in angiotensin-converting enzyme and angiotensin-converting enzyme 2 are not associated with thoracic aortic diseases and coronary heart disease
    Li, Yang
    Zhang, Er Yong
    Wu, Zhong
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2016, 25 (03) : 148 - 151